FDA Archives - Page 46 of 220

2 minute read

FDA Greenlights Expanded Use Of Neurocrine Biosciences’ Ingrezza: Analysts Weigh In Depression Warning

August 21, 2:24 PM

The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated

NBIX

1 minute read

FDA Pauses Gilead’s Investigational Magrolimab Study In Blood Cancer Patients

By Vandana Singh

August 21, 11:46 AM

FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S.

GILD

1 minute read

FDA Approves Regeneron’s Drug For Ultra Rare Immune Disorder

By Vandana Singh

August 21, 10:18 AM

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient

REGN

1 minute read

FDA Approves Regeneron Pharmaceuticals’ Higher Dose Of Eylea For Age-Related Blindness

By Vandana Singh

August 21, 8:37 AM

The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),

BAYRY

3 minute read

Neurocrine Biosciences Announces FDA Approval Of INGREZZA Capsules For The Treatment Of Chorea Associated With Huntington’s Disease

By Happy Mohamed

August 18, 4:36 PM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated

NBIX

3 minute read

FDA
News

CHP Investigates Two Confirmed Mpox Cases

By Benzinga Newsdesk

August 18, 9:00 AM

The Centre for Health Protection (CHP) of the Department of Health (DH) said today (August 18) that it is investigating two confirmed Mpox (also known as Monkeypox) cases, and urged the public to heighten vigilance

AEMD

2 minute read

MediWound Announces Collaboration With MIMEDX On EscharEx Phase III Study

By Happy Mohamed

August 15, 4:09 PM

MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with

MDWD

2 minute read

MediWound Announces Collaboration With Mölnlycke On EscharEx Phase III Study

By Happy Mohamed

August 15, 4:08 PM

MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced a research collaboration agreement with Mölnlycke for

MDWD